The study results showed increase in lumbar spine bone mineral density at month 12 for the AMG 785/CDP7851 active arms versus the placebo arm.
The study was planned to investigate the effect of AMG 785/CDP7851 as compare to placebo in women with low BMD, and to find out the safety and tolerability of AMG 785/CDP7851.
Both companies are now planning to start the in depth analysis of the data to prepare for the Phase 3 program.
Amgen Research and Development executive vice president Roger Perlmutter said they look forward to working with UCB to advance the AMG 785/CDP7851 program into Phase 3.
UCB chief medical officer Iris Loew-Friedrich said the favorable comparison with established therapies indicates the potential for a change of treatment paradigms with AMG 785/CDP7851 in PMO.